

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5715255

|                              |                |
|------------------------------|----------------|
| <b>SUBMISSION TYPE:</b>      | NEW ASSIGNMENT |
| <b>NATURE OF CONVEYANCE:</b> | RESCISSION     |

**CONVEYING PARTY DATA**

| Name            | Execution Date |
|-----------------|----------------|
| MICHAEL HAR-NOY | 09/12/2019     |

**RECEIVING PARTY DATA**

|                        |                        |
|------------------------|------------------------|
| <b>Name:</b>           | MICHAEL HAR-NOY        |
| <b>Street Address:</b> | 16 WASHINGTON ST,B3-61 |
| <b>City:</b>           | JERUSALEM              |
| <b>State/Country:</b>  | ISRAEL                 |
| <b>Postal Code:</b>    | 9695101                |

**PROPERTY NUMBERS Total: 62**

| Property Type       | Number   |
|---------------------|----------|
| Application Number: | 16215116 |
| Application Number: | 15630592 |
| Application Number: | 15630581 |
| Application Number: | 15084206 |
| Application Number: | 15245845 |
| Application Number: | 16433659 |
| Application Number: | 14962728 |
| Application Number: | 15003437 |
| Application Number: | 15003447 |
| Application Number: | 15077493 |
| Application Number: | 16434977 |
| Application Number: | 15077525 |
| Application Number: | 15922600 |
| Application Number: | 15041642 |
| Application Number: | 15691395 |
| Application Number: | 62614818 |
| Application Number: | 62618442 |
| Application Number: | 62629311 |
| Application Number: | 62614838 |
| Application Number: | 62618446 |

PATENT

| <b>Property Type</b> | <b>Number</b> |
|----------------------|---------------|
| Application Number:  | 62621393      |
| Application Number:  | 62638647      |
| Application Number:  | 62814698      |
| Application Number:  | 10838454      |
| Application Number:  | 11066133      |
| Application Number:  | 11069010      |
| Application Number:  | 11251585      |
| Application Number:  | 11936948      |
| Application Number:  | 11601446      |
| Application Number:  | 12172594      |
| Application Number:  | 12434168      |
| Application Number:  | 12173330      |
| Application Number:  | 12570442      |
| Application Number:  | 12533668      |
| Application Number:  | 12687281      |
| Application Number:  | 12869490      |
| Application Number:  | 12967910      |
| Application Number:  | 12909517      |
| Application Number:  | 12817512      |
| Application Number:  | 13084900      |
| Application Number:  | 13214534      |
| Application Number:  | 12887054      |
| Application Number:  | 12887039      |
| Application Number:  | 13581895      |
| Application Number:  | 13581745      |
| Application Number:  | 13077347      |
| Application Number:  | 13099867      |
| Application Number:  | 13099871      |
| Application Number:  | 13150893      |
| Application Number:  | 13187991      |
| Application Number:  | 13659290      |
| Application Number:  | 13796171      |
| Application Number:  | 13596142      |
| Application Number:  | 13800193      |
| Application Number:  | 13800066      |
| Application Number:  | 14592701      |
| Application Number:  | 14173494      |
| Application Number:  | 14301700      |

| Property Type       | Number   |
|---------------------|----------|
| Application Number: | 14206785 |
| Application Number: | 14193832 |
| Application Number: | 14500381 |
| Application Number: | 14500395 |

**CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 972542327077

**Email:** harnoy@immunovative.com

**Correspondent Name:** MICHAEL HAR-NOY

**Address Line 1:** 16 WASHINGTON ST,B3-61

**Address Line 4:** JERUSALEM, ISRAEL 9695101

|                           |  |
|---------------------------|--|
| <b>NAME OF SUBMITTER:</b> | MICHAEL HAR-NOY  |
| <b>SIGNATURE:</b>         | /Michael Har-Noy/  |
| <b>DATE SIGNED:</b>       | 09/12/2019   |
|                           | This document serves as an Oath/Declaration (37 CFR 1.63). |

**Total Attachments: 4**

source=Rescission of Assignments-Har-Noy#page1.tif

source=Rescission of Assignments-Har-Noy#page2.tif


source=Rescission of Assignments-Har-Noy#page3.tif

source=Rescission of Assignments-Har-Noy#page4.tif

# RESCISSION OF ASSIGNMENTS

Whereas, I, Michael Har-Noy having a current residence at King David Court, 16 George Washington Street, B3-61, Jerusalem, Israel 9418706 (formerly Modi'in, Israel) (hereinafter referred to as "Assignor") am the sole inventor of the inventions described in the patent applications for letters patent and granted letters patent as listed in Exhibit A attached hereto and have previously assigned my rights in these inventions, patent applications and granted patents by and through a number of assignments to Immunovative Therapies, Ltd. ("Assignee") an Israel corporation having a place of business at Malcha Technology Park, 1 Agudat Sport Hapoal Street, Jerusalem 9695101 Israel, the assignments identified in Exhibit A having been recorded in the United States Patent and Trademark Office; I do hereby rescind any and all rights, title and interest in and to the inventions, the applications and any and all Letters Patent(s) or similar legal protection, foreign or domestic, to be obtained and has been obtained. This rescission action is taken due to the fact that the previous assignments were made without any contractual agreement and the Assignee has failed to provide any consideration.

## ASSIGNOR



---

Date September 12, 2019

**EXHIBIT A**

| Application Number | Patent Number | Title  |
|--------------------|---------------|--|
| 16/215116          |               | VACCINE COMPOSITIONS AND METHODS   |
| 15/630592          |               | TH 1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPY                            |
| 15/630581          |               | KIT FOR INCREASING Th1 CELLS   |
| 15/084206          |               | COMPOSITIONS FOR LIQUIDATION OF TUMORS                                       |
| 15/245845          |               | METHODS AND COMPOSITIONS FOR INHIBITION OF TREG CELLS                        |
| 16/433659          |               | METHODS FOR HANDLING BIOLOGICAL DRUGS CONTAINING LIVING CELLS                |
| 14/962728          |               | INDUCTION OF IL-12 USING IMMUNOTHERAPY                                       |
| 15/003437          |               | ABLATIVE IMMUNOTHERAPY   |
| 15/003447          |               | ABLATIVE IMMUNOTHERAPY   |
| 15/077493          | 10318712      | AUTOMATED DEVICE FOR A BIOLOGIC DRUG DISTRIBUTION                            |
| 16/434977          |               | AUTOMATED DEVICE FOR A BIOLOGIC DRUG DISTRIBUTION                            |
| 15/077525          |               | ABLATIVE IMMUNOTHERAPY   |
| 15/922600          |               | TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME |
| 15/041642          | 9782463       | METHOD FOR ALLOGENEIC CELL THERAPY   |
| 15/691395          |               | METHOD FOR ALLOGENEIC CELL THERAPY   |
|                    |               | METHOD OF PROVIDING A BIOLOGICAL PHARMACEUTICAL                              |
| 62/614818          |               | THERAPEUTIC METHODS AND COMPOSITIONS FOR ADVANCED LIVER CANCER               |
| 62/618442          |               | THERAPEUTIC METHODS AND COMPOSITIONS FOR ADVANCED LIVER CANCER               |
| 62/629311          |               | THERAPEUTIC METHODS AND COMPOSITIONS FOR ADVANCED LIVER CANCER               |
|                    |               | THERAPEUTIC METHODS AND COMPOSITIONS FOR ADVANCED LIVER CANCER               |
| 62/614838          |               | THERAPEUTIC METHODS AND COMPOSITIONS FOR METASTATIC COLORECTAL CANCER        |
| 62/618446          |               | THERAPEUTIC METHODS AND COMPOSITIONS FOR METASTATIC COLORECTAL CANCER        |

|                  |         |  |
|------------------|---------|--|
| <b>62/621393</b> |         | THERAPEUTIC METHODS AND COMPOSITIONS FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA             |
| <b>62/638647</b> |         | PROCESS AND APPARATUS FOR PRODUCING A BIOLOGICAL PRODUCT                                   |
| <b>62/814698</b> |         | PROCESS AND APPARATUS FOR PRODUCING A BIOLOGICAL PRODUCT                                   |
|                  |         | METHOD FOR TREATING CHEMOTHERAPY-RESISTANT METASTATIC DISEASE                              |
| <b>10/838454</b> | 7435592 | COMPOSITIONS FOR ALLOGENEIC CELL THERAPY   |
| <b>11/066133</b> | 7678572 | METHODS FOR PREPARING T-CELLS FOR CELL THERAPY   |
| <b>11/069010</b> | 7402431 | T-CELL THERAPY FORMULATION   |
| <b>11/251585</b> | 8865224 | ALLOGENEIC CELLULAR IMMUNOTHERAPY FOR OPPORTUNISTIC INFECTION                              |
| <b>11/936948</b> | 7972594 | ABLATIVE IMMUNOTHERAPY   |
| <b>11/601446</b> | 7592431 | BIODEGRADABLE T-CELL ACTIVATION DEVICE AND METHODS   |
| <b>12/172594</b> | 7943180 | A METHOD FOR STIMULATING A HOST IMMUNE SYSTEM BY ADMINISTERING AN ALLOGENEIC CELL MATERIAL |
| <b>12/434168</b> |         | VACCINE COMPOSITIONS AND METHODS   |
| <b>12/173330</b> | 8076135 | METHOD OF PREPARING A TREATMENT EFFECTIVE AMOUNT OF ALLOGENEIC T-CELLS                     |
| <b>12/570442</b> | 9695397 | TH 1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPY  |
| <b>12/533668</b> | 8012750 | METHOD FOR ACTIVATING T-CELLS  |
| <b>12/687281</b> | 7956164 | DEVICE FOR ENHANCING IMMUNOSTIMULATORY CAPABILITIES OF T-CELLS                             |
| <b>12/869490</b> | 8273377 | A METHOD FOR ALLOGENEIC CELL THERAPY   |
| <b>12/967910</b> |         | METHODS AND COMPOSITIONS FOR LIQUIDATION OF TUMORS   |
| <b>12/909517</b> | 8354276 | ALLOGENEIC CELL COMPOSITIONS THAT ELICIT TYPE I CYTOKINE RESPONSE                          |
| <b>12/817512</b> | 8071374 | METHODS FOR PREPARING T-CELLS FOR CELL THERAPY   |
| <b>13/084900</b> |         | METHODS AND COMPOSITIONS FOR INHIBITION OF TREG CELLS                                      |
| <b>13/214534</b> |         | CELLS EXPRESSING GRANZYME B AND PERFORIN   |
| <b>12/887054</b> | 8778678 | COMPOSITION OF ACTIVATED CD4 CELLS   |
| <b>12/887039</b> | 8785188 | METHOD TO FORMULATE T-   |

| CELLS            |          |  |
|------------------|----------|--|
| <b>13/581895</b> | 10350242 | METHODS FOR HANDLING BIOLOGICAL DRUGS CONTAINING LIVING CELLS                |
| <b>13/581745</b> | 9233156  | INDUCTION OF IL-12 USING IMMUNOTHERAPY                                       |
| <b>13/077347</b> | 8883974  | DEVICE FOR ENHANCING IMMUNOSTIMULATORY CAPABILITIES OF T-CELLS               |
| <b>13/099867</b> | 8728534  | METHOD FOR STIMULATING A HOST IMMUNE SYSTEM                                  |
| <b>13/099871</b> | 8298587  | METHOD FOR STIMULATING A THERAPEUTIC IMMUNE EFFECT IN A PATIENT              |
| <b>13/150893</b> | 9272001  | ABLATIVE IMMUNOTHERAPY   |
| <b>13/187991</b> | 8313944  | METHODS TO CAUSE DIFFERENTIATION OF T-CELLS FOR USE IN CELL THERAPY          |
| <b>13/659290</b> |          | AUTOMATED DEVICE FOR A BIOLOGIC DRUG DISTRIBUTION                            |
| <b>13/796171</b> | 9320794  | ABLATIVE IMMUNOTHERAPY   |
| <b>13/596142</b> | 8679841  | ALLOGENEIC CELL COMPOSITION WITH CROSS-LINKED CD3/CD28                       |
| <b>13/800193</b> | 10385315 | CELLS EXPRESSING TH1 CHARACTERISTICS AND CYTOLYTIC PROPERTIES                |
| <b>13/800066</b> |          | CELLS EXPRESSING TH1 CHARACTERISTICS AND CYTOLYTIC PROPERTIES                |
| <b>14/592701</b> | 10272143 | TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS/ACQUIRED IMMUNODEFICIENCY SYNDROME |
| <b>14/173494</b> | 9301977  | METHOD FOR ALLOGENEIC CELL THERAPY   |
| <b>14/301700</b> | 9511127  | METHOD TO FORMULATE T-CELLS  |
| <b>14/206785</b> | 9352001  | METHOD FOR STIMULATING A HOST IMMUNE SYSTEM                                  |
| <b>14/193832</b> |          | METHODS AND COMPOSITIONS FOR LIQUIDATION OF TUMORS                           |
| <b>14/500381</b> | 9593308  | DEVICE FOR ENHANCING IMMUNOSTIMULATORY CAPABILITIES OF T-CELLS               |
| <b>14/500395</b> |          | ALLOGENEIC CELLULAR IMMUNOTHERAPY FOR OPPORTUNISTIC INFECTION                |